---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-010711"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:38:22.327300+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada acquires Sepranolone for €3M; Phase 2b-ready for Tourette syndrome

## Summary
- Acquired Sepranolone (GAMSA neurosteroid) from Asarina Pharma AB for €3 million; €2.756M due within 10 business days.
- Phase 2a data: 28% reduction in tic severity (YGTSS, p=0.051); 69% greater quality-of-life improvement vs standard of care.
- Phase 2b-ready asset for Tourette syndrome and other compulsive disorders; no CNS off-target effects in Phase 2a.
- Relmada to host investor update on next development steps later in 2025.
- Deal includes full global ownership rights; Asarina retains pre-closing liabilities.

## SEC filing metadata
- accession: 0001213900-25-010711
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025010711/0001213900-25-010711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025010711/ea0230164-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-010711
- JSON: https://secwatch.observer/filing/0001213900-25-010711.json
- Plain text: https://secwatch.observer/filing/0001213900-25-010711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.